These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30446370)

  • 21. Serum endocan levels in multiple sclerosis relapse and remission.
    Akil E; Alp R; Aluclu MU; Acar A; Kaplan I
    Eur Rev Med Pharmacol Sci; 2021 Jun; 25(11):4091-4098. PubMed ID: 34156688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Degenerative and inflammatory markers in the cerebrospinal fluid of multiple sclerosis patients with relapsing-remitting course of disease and after clinical isolated syndrome.
    Sladkova V; Mareš J; Lubenova B; Zapletalova J; Stejskal D; Hlustik P; Kanovsky P
    Neurol Res; 2011 May; 33(4):415-20. PubMed ID: 21535941
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Albumin and Protein Oxidation are Predictors that Differentiate Relapsing-Remitting from Progressive Clinical Forms of Multiple Sclerosis.
    Oliveira SR; Kallaur AP; Reiche EMV; Kaimen-Maciel DR; Panis C; Lozovoy MAB; Morimoto HK; Maes M; Dichi I; Simão ANC
    Mol Neurobiol; 2017 May; 54(4):2961-2968. PubMed ID: 27026183
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis.
    Novakova L; Axelsson M; Khademi M; Zetterberg H; Blennow K; Malmeström C; Piehl F; Olsson T; Lycke J
    J Neurochem; 2017 Apr; 141(2):296-304. PubMed ID: 27787906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum uric acid level in patients with relapsing-remitting multiple sclerosis.
    Ashtari F; Bahar M; Aghaei M; Zahed A
    J Clin Neurosci; 2013 May; 20(5):676-8. PubMed ID: 23528410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cervical cord area is associated with infratentorial grey and white matter volume predominantly in relapsing-remitting multiple sclerosis: A study using semi-automated cord volumetry and voxel-based morphometry.
    Bellenberg B; Schneider R; Weiler F; Suchan B; Haghikia A; Hoffjan S; Gold R; Köster O; Lukas C
    Mult Scler Relat Disord; 2015 May; 4(3):264-72. PubMed ID: 26008944
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased cerebrospinal fluid chitotriosidase index in patients with multiple sclerosis.
    Verbeek MM; Notting EA; Faas B; Claessens-Linskens R; Jongen PJ
    Acta Neurol Scand; 2010 May; 121(5):309-14. PubMed ID: 19925532
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chitinase effects on immune cell response in neuromyelitis optica and multiple sclerosis.
    Correale J; Fiol M
    Mult Scler; 2011 May; 17(5):521-31. PubMed ID: 21159721
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of orexin-A and neurofilament light chain levels in patients with relapsing-remitting multiple sclerosis: a pilot study.
    Saruhan E; Korkmaz M; Altiparmak B; Tosun K; Kutlu G
    Ideggyogy Sz; 2022 Jul; 75(7-08):223-230. PubMed ID: 35916608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CSF levels of soluble HLA-G and Fas molecules are inversely associated to MRI evidence of disease activity in patients with relapsing-remitting multiple sclerosis.
    Fainardi E; Rizzo R; Melchiorri L; Stignani M; Castellazzi M; Tamborino C; Paolino E; Tola MR; Granieri E; Baricordi OR
    Mult Scler; 2008 May; 14(4):446-54. PubMed ID: 18208868
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Micro-RNA 18b and interleukin 17A profiles in relapsing remitting multiple sclerosis.
    Mohamed MS; Nahrery EMAE; Shalaby N; Hussein M; Aal RAE; Mohamed MM
    Mult Scler Relat Disord; 2019 Feb; 28():226-229. PubMed ID: 30623862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum anti-Glc(alpha1,4)Glc(alpha) antibodies as a biomarker for relapsing-remitting multiple sclerosis.
    Schwarz M; Spector L; Gortler M; Weisshaus O; Glass-Marmor L; Karni A; Dotan N; Miller A
    J Neurol Sci; 2006 May; 244(1-2):59-68. PubMed ID: 16480743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cerebrospinal fluid and plasma oxidative stress biomarkers in different clinical phenotypes of neuroinflammatory acute attacks. Conceptual accession: from fundamental to clinic.
    Ljubisavljevic S; Stojanovic I; Vojinovic S; Stojanov D; Stojanovic S; Kocic G; Savic D; Cvetkovic T; Pavlovic D
    Cell Mol Neurobiol; 2013 Aug; 33(6):767-77. PubMed ID: 23677512
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone.
    Öhrfelt A; Axelsson M; Malmeström C; Novakova L; Heslegrave A; Blennow K; Lycke J; Zetterberg H
    Mult Scler; 2016 Oct; 22(12):1587-1595. PubMed ID: 26754805
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determination of soluble ICAM-1 and TNFalphaR in the cerebrospinal fluid and serum levels in a population of Brazilian patients with relapsing-remitting multiple sclerosis.
    Alves-Leon SV; Batista E; Papais-Alvarenga R; Quírico-Santos T
    Arq Neuropsiquiatr; 2001 Mar; 59(1):18-22. PubMed ID: 11299425
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis.
    Martínez MA; Olsson B; Bau L; Matas E; Cobo Calvo Á; Andreasson U; Blennow K; Romero-Pinel L; Martínez-Yélamos S; Zetterberg H
    Mult Scler; 2015 Apr; 21(5):550-61. PubMed ID: 25732842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression.
    Teunissen CE; Sombekke M; van Winsen L; Killestein J; Barkhof F; Polman CH; Dijkstra CD; Blankenstein MA; Pratico D
    Mult Scler; 2012 Aug; 18(8):1092-8. PubMed ID: 22695538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis.
    Brettschneider J; Petzold A; Junker A; Tumani H
    Mult Scler; 2006 Apr; 12(2):143-8. PubMed ID: 16629417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intrathecal K free light chain synthesis in multiple sclerosis at clinical onset associates with local IgG production and improves the diagnostic value of cerebrospinal fluid examination.
    Puthenparampil M; Altinier S; Stropparo E; Zywicki S; Poggiali D; Cazzola C; Toffanin E; Ruggero S; Grassivaro F; Zaninotto M; Plebani M; Gallo P
    Mult Scler Relat Disord; 2018 Oct; 25():241-245. PubMed ID: 30130707
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNA 26a Expression in Peripheral Blood Mononuclear Cells and Correlation with Serum Interleukin-17 in Relapsing-Remitting Multiple Sclerosis Patients.
    Mahmoud FM; ElSheshtawy NM; Zaki WK; Zamzam DM; Fahim NM
    Egypt J Immunol; 2017 Jun; 24(2):71-82. PubMed ID: 29528581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.